TQB 3107
Alternative Names: TQB-3107Latest Information Update: 22 Jul 2024
Price :
$50 *
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Cell proliferation modulators; Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Jun 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT06413953)
- 14 May 2024 Chia Tai Tianqing Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO, Tablet) in May 2024 (NCT06413953)
- 14 May 2024 Preclinical trials in Solid tumours in China (PO) before May 2024